# Management of Retinopathy of Prematurity in the United Arab Emirates: A Consensus Statement From the Emirates Society of Ophthalmology

**Authors:** Abeer K Al Ali, Noura Al Qassimi, Hanan Al Shamsi, Syed Muhammad Asad Ali, Tulika Kar MS, Laila Obaid, Firdaus Sukhi, Hassan Salim Al Hasid, Ayesha Khan, Muhammad Irfan Khan, Darakhshanda Khurram

PMC · DOI: 10.7759/cureus.103096 · Cureus · 2026-02-06

## TL;DR

This paper presents a national consensus on managing retinopathy of prematurity in the UAE to prevent childhood blindness and improve outcomes for preterm infants.

## Contribution

The paper provides UAE-specific, expert consensus guidelines for ROP detection, management, and system-level improvements.

## Key findings

- Timely laser photocoagulation and anti-VEGF therapy are recommended for treating ROP in the UAE.
- System-level and educational gaps hinder effective ROP management and require targeted interventions.
- Integrated tracking and neonatologist engagement are critical for long-term ROP prevention and follow-up.

## Abstract

Retinopathy of prematurity (ROP) is a leading cause of preventable childhood blindness worldwide and affects a substantial proportion of very preterm or very-low-birth-weight infants. In the United Arab Emirates (UAE), hospital-based cohorts report a notable incidence of ROP among preterm infants, underscoring the need for standardized protocols.

This Nominal Group Technique (NGT)-based national expert consensus aims to provide unified guidance for early detection, effective management, and improved outcomes for infants at risk of ROP in the UAE. A nationally representative panel of UAE-based consultant ophthalmologists, with neonatologists as non-voting advisors, developed recommendations for the International Classification of Retinopathy of Prematurity, Third Edition (ICROP-III) classification, screening, and management. Key management strategies include timely laser photocoagulation for treatment-requiring ROP, where feasible, and intravitreal anti-vascular endothelial growth factor (VEGF) therapy as a preferred or initial option in posterior disease and aggressive ROP (A-ROP), with prolonged surveillance for reactivation.

Unmet needs include system-level gaps (standardized documentation, integrated tracking, and follow-up pathways) and educational gaps, particularly neonatologist and neonatal intensive care unit (NICU) staff engagement in prevention and long-term follow-up.

## Linked entities

- **Diseases:** Retinopathy of Prematurity (MONDO:0006952), ROP (MONDO:0006952)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}
- **Diseases:** vitreous hemorrhage (MESH:D014823), strabismus (MESH:D013285), lens injury (MESH:D007905), intraventricular hemorrhage (MESH:D000074042), tachycardia (MESH:D013610), hypoxic (MESH:D002534), hemorrhage (MESH:D006470), -ROP (MESH:D012178), weight gain (MESH:D015430), intraocular bleeding (MESH:D064090), burn (MESH:D002056), bradycardia (MESH:D001919), hypoxia (MESH:D000860), blindness (MESH:D001766), abnormal retinal vascular development (MESH:D058456), respiratory distress syndrome (MESH:D012128), retinal detachment (MESH:D012163), Pupil dilation (MESH:D011681), vascular occlusion (MESH:D008641), Hyperoxia (MESH:D018496), vision loss (MESH:D014786), fibrosis (MESH:D005355), impaired fetal growth (MESH:D005317), Plus disease (MESH:D004194), edema (MESH:D004487), high myopia (MESH:D009216), preeclampsia (MESH:D011225), macular abnormalities (MESH:D008268), vascular abnormalities (MESH:D014652), maternal diabetes (MESH:D003920), retinal hemorrhage (MESH:D012166), growth failure (MESH:D051437), extreme prematurity (MESH:C536271), retinal disease (MESH:D012164), glaucoma (MESH:D005901), necrotizing enterocolitis (MESH:D020345), depression (MESH:D003866), cataract (MESH:D002386), ill (MESH:D002908), sepsis (MESH:D018805), Zone I disease (MESH:D009081), vascular anomalies (MESH:D020785), refractive error (MESH:D012030), cardiorespiratory instability (MESH:D043171), apnea of prematurity (MESH:D001049), III (MESH:C537189), hypertension (MESH:D006973), anemia (MESH:D000740), PAR (MESH:D019572), bronchopulmonary dysplasia (MESH:D001997), retinal injury (MESH:D012173), premature birth (MESH:D047928), infection (MESH:D007239)
- **Chemicals:** methicillin (MESH:D008712), Bevacizumab (MESH:D000068258), moxifloxacin (MESH:D000077266), oxygen (MESH:D010100), cyclopentolate (MESH:D003519), tropicamide (MESH:D014331), phenylephrine (MESH:D010656), sucrose (MESH:D013395), povidone-iodine (MESH:D011206), morphine (MESH:D009020), caffeine (MESH:D002110), ketamine (-), ranibizumab (MESH:D000069579)
- **Species:** Homo sapiens (human, species) [taxon 9606], Staphylococcus aureus (species) [taxon 1280]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967806/full.md

## References

99 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967806/full.md

---
Source: https://tomesphere.com/paper/PMC12967806